Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
701 studies found for:    Open Studies | "Lymphoma, Non-Hodgkin"
Show Display Options
Rank Status Study
21 Not yet recruiting A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Conditions: Lymphoma, Non-Hodgkin;   Neoplasms
Intervention: Drug: CC-90011
22 Recruiting Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma
Interventions: Drug: Carfilzomib;   Drug: Bendamustine;   Drug: Rituximab
23 Recruiting Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease
Conditions: Lymphoma, Non-Hodgkin;   Hodgkin's Disease
Intervention:
24 Recruiting A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.
Conditions: Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Non-Hodgkin
Interventions: Drug: Obinutuzumab;   Drug: CC-122
25 Not yet recruiting Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma
Conditions: Hodgkin Disease;   Lymphoma, Non-hodgkin
Interventions: Drug: Carfilzomib;   Drug: TGR-1202
26 Recruiting Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma
Conditions: Hodgkin's Lymphoma;   Lymphoma, Non-Hodgkin
Interventions: Drug: Bortezomib;   Drug: Ruxolitinib
27 Recruiting A Safety and Pharmacokinetic Study of BTCT4465A in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Condition: Lymphocytic Leukemia, Chronic, Lymphoma, Non Hodgkin
Intervention: Drug: BTCT4465A
28 Recruiting TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Conditions: Lymphoma, Non-Hodgkin;   Multiple Myeloma;   Advanced Solid Tumors
Interventions: Drug: Erlotinib;   Drug: Axitinib;   Drug: Bosutinib;   Drug: Crizotinib;   Drug: Palbociclib;   Drug: Sunitinib;   Drug: Temsirolimus;   Drug: Trastuzumab and Pertuzumab;   Drug: Vemurafenib and Cobimetinib;   Drug: Vismodegib;   Drug: Cetuximab;   Drug: Dasatinib;   Drug: Regorafenib;   Drug: Olaparib;   Drug: Pembrolizumab
29 Recruiting Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma, Large B-Cell, Diffuse;   Indolent Lymphoma
Interventions: Drug: Hu5F9-G4;   Drug: Rituximab
30 Not yet recruiting Symbenda Post-Marketing Surveillance (PMS)
Conditions: Lymphoma, Non-Hodgkin;   Lymphocytic Leukemia;   Multiple Myeloma
Intervention:
31 Recruiting Epidemiology of Burkitt Lymphoma in East Africa Children or Minors (EMBLEM)
Conditions: Lymphoma, Non-Hodgkin;   Malaria;   Herpesvirus 4, Human
Intervention:
32 Recruiting Yoga to Alleviate Fatigue, Anxiety and Pain in Adolescents During Treatment for Lymphoma or Leukemia
Conditions: Leukemia;   Hodgkin Lymphoma;   Lymphoma, Non-Hodgkin's
Interventions: Other: PedsQL Cancer Module;   Other: PedsQL Multidimensional Fatigue Scale;   Device: Biodex System 3 Dynamometer;   Device: Jamar Hydraulic Hand Dynamometer;   Other: Sit and Reach Test;   Other: Test of Motor Proficiency;   Other: Verbal Numeric Pain Scale;   Other: :Yoga Therapy
33 Recruiting Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Conditions: Lymphoid Leukemia;   Small Lymphocytic Lymphoma;   Lymphoma, Non-Hodgkin
Interventions: Drug: Bendamustine Hydrochloride;   Drug: Rituximab;   Drug: Lenalidomid
34 Recruiting Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Conditions: B-Cell Prolymphocytic Leukemia;   Plasma Cell Leukemia;   Progression of Multiple Myeloma or Plasma Cell Leukemia;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Childhood Hodgkin Lymphoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Non-Hodgkin Lymphoma;   Refractory Plasma Cell Myeloma;   Refractory Small Lymphocytic Lymphoma;   T-Cell Prolymphocytic Leukemia;   Waldenstrom Macroglobulinemia
Interventions: Procedure: Allogeneic Bone Marrow Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Procedure: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
35 Available A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001
Conditions: Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin;   Lymphoma, T-Cell, Cutaneous
Intervention: Drug: brentuximab vedotin
36 Recruiting Study of Lymphoma in Asia
Conditions: Lymphoma, Non-Hodgkin;   Multiple Myleoma;   Lympocytic, Follicular;   Leukemia;   Hodgkin Lymphoma
Intervention:
37 Recruiting T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
Conditions: Lymphoma, B-Cell;   Lymphoma, Non-hodgkins;   Lymphoma, Hodgkins;   Leukemia, B-cell
Interventions: Biological: Anti-CD19-CAR T cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
38 Recruiting Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Conditions: Acute Lymphoblastic Leukemia;   Lymphoma, Non-Hodgkin's;   Leukemia, T-Cell;   Leukemia, B-Cell
Interventions: Drug: Dexamethasone;   Drug: Panobinostat;   Drug: Liposomal vincristine;   Drug: Mitoxantrone;   Drug: Peg-asparaginase;   Drug: Bortezomib;   Drug: Intrathecal Triples;   Drug: High-dose methotrexate;   Drug: 6-Mercaptopurine;   Drug: High-dose cytarabine;   Drug: Nelarabine;   Drug: Cyclophosphamide;   Drug: Etoposide;   Drug: Clofarabine
39 Recruiting Phase I/II MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
Conditions: Myeloid Leukemia, Chronic;   Acute Myelogenous Leukemia;   Myelodysplastic Syndromes (MDS);   Lymphoma, Non-Hodgkin
Intervention: Biological: Conventional T cells (Tcon) and Regulatory T cells (Treg)
40 Not yet recruiting Development of a Tissue-Based & Cell Free DNA Next-Generation Sequencing Workflow
Condition: Non-Hodgkin Lymphoma
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.